SLU-PP-332

SLU-PP-332 is a synthetic compound developed at Saint Louis University that functions as a pan-agonist of estrogen-related receptors (ERRs), specifically targeting ERRa, ERRb, and ERRg with highest potency at ERRa. Estrogen-related receptors are nuclear transcription factors that regulate gene networks governing oxidative metabolism, mitochondrial biogenesis, and energy homeostasis. Because these pathways are also activated by endurance exercise, SLU-PP-332 is classified as an exercise mimetic: a compound that reproduces cellular adaptations associated with aerobic physical activity through pharmacological means rather than mechanical work.

The molecular mechanism centers on ERRa's control of the DDIT4 (DNA damage-inducible transcript 4) pathway. Research published in ACS Chemical Biology (2022) demonstrated that SLU-PP-332 treatment induces DDIT4 expression specifically through ERRa activation ^[1], recapitulating a key genetic response observed after short bouts of aerobic exercise in humans. Downstream of this activation, genes encoding proteins involved in fatty acid oxidation, oxidative phosphorylation, and mitochondrial function are upregulated in skeletal muscle cells, producing a metabolic state resembling aerobic-trained muscle. This mechanism is distinct from REV-ERB agonists like SR-9011 or PPAR delta agonists like GW501516; ERR agonists occupy a unique node in the exercise-responsive transcriptional network.

In animal studies, SLU-PP-332 produced measurable gains in exercise endurance. Mice treated with the compound and placed on running protocols showed 20 to 30% improvements in running distance and time compared to vehicle-treated controls, along with increased proportions of type IIa oxidative muscle fibers, which are associated with sustained aerobic effort. Whole-body metabolic studies showed increased energy expenditure and enhanced fatty acid oxidation, accompanied by reduced fat mass accumulation over time without changes in food intake. A 2023 study published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that ERRa agonism with SLU-PP-332 effectively reduced obesity and improved insulin sensitivity in murine models of metabolic syndrome ^[2].

The research interest in SLU-PP-332 extends to its potential role in aging, sarcopenia, and conditions where exercise capacity is limited by disease or disability. The ability to pharmacologically engage aerobic exercise gene programs could theoretically benefit patients with heart failure, COPD, mobility limitations, or severe obesity who cannot engage in sufficient physical activity. No human clinical trials have been initiated as of early 2026, and all efficacy and safety data are preclinical.